Literature DB >> 21969018

Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.

Joanna Pepke-Zaba1, Marion Delcroix, Irene Lang, Eckhard Mayer, Pavel Jansa, David Ambroz, Carmen Treacy, Andrea M D'Armini, Marco Morsolini, Repke Snijder, Paul Bresser, Adam Torbicki, Bent Kristensen, Jerzy Lewczuk, Iveta Simkova, Joan A Barberà, Marc de Perrot, Marius M Hoeper, Sean Gaine, Rudolf Speich, Miguel A Gomez-Sanchez, Gabor Kovacs, Abdul Monem Hamid, Xavier Jaïs, Gérald Simonneau.   

Abstract

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism with fatal natural history; however, many cases can be cured by pulmonary endarterectomy. The clinical characteristics and current management of patients enrolled in an international CTEPH registry was investigated. METHODS AND
RESULTS: The international registry included 679 newly diagnosed (≤6 months) consecutive patients with CTEPH, from February 2007 until January 2009. Diagnosis was confirmed by right heart catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary angiography. At diagnosis, a median of 14.1 months had passed since first symptoms; 427 patients (62.9%) were considered operable, 247 (36.4%) nonoperable, and 5 (0.7%) had no operability data; 386 patients (56.8%, ranging from 12.0%- 60.9% across countries) underwent surgery. Operable patients did not differ from nonoperable patients relative to symptoms, New York Heart Association class, and hemodynamics. A history of acute pulmonary embolism was reported for 74.8% of patients (77.5% operable, 70.0% nonoperable). Associated conditions included thrombophilic disorder in 31.9% (37.1% operable, 23.5% nonoperable) and splenectomy in 3.4% of patients (1.9% operable, 5.7% nonoperable). At the time of CTEPH diagnosis, 37.7% of patients initiated at least 1 pulmonary arterial hypertension-targeted therapy (28.3% operable, 53.8% nonoperable). Pulmonary endarterectomy was performed with a 4.7% documented mortality rate.
CONCLUSIONS: Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct associated medical conditions. Operability rates vary considerably across countries, and a substantial number of patients (operable and nonoperable) receive off-label pulmonary arterial hypertension-targeted treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969018     DOI: 10.1161/CIRCULATIONAHA.110.015008

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  181 in total

1.  AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis.

Authors:  Wanmu Xie; Lin Zhang; Wei Luo; Zhenguo Zhai; Chen Wang; Ying H Shen
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

2.  Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Yu Taniguchi; Philippe Brenot; Xavier Jais; Carlos Garcia; Jason Weatherald; Olivier Planche; Elie Fadel; Marc Humbert; Gérald Simonneau
Journal:  Chest       Date:  2018-05-03       Impact factor: 9.410

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Noninvasive pulmonary artery pressure monitoring by EIT: a model-based feasibility study.

Authors:  Martin Proença; Fabian Braun; Josep Solà; Jean-Philippe Thiran; Mathieu Lemay
Journal:  Med Biol Eng Comput       Date:  2016-09-17       Impact factor: 2.602

5.  Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Soundos Saleh; Corina Becker; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 6.  Imaging of Chronic Thromboembolic Disease.

Authors:  Adina Haramati; Linda B Haramati
Journal:  Lung       Date:  2020-03-12       Impact factor: 2.584

7.  Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Authors:  John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba
Journal:  Circulation       Date:  2016-04-06       Impact factor: 29.690

8.  Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical Centers.

Authors:  David Furfaro; Javad Azadi; Traci Housten; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Kelly Chin; Stephen C Mathai
Journal:  Ann Am Thorac Soc       Date:  2019-02

9.  Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.

Authors:  Evandro M Neto-Neves; Mary B Brown; Maria V Zaretskaia; Samin Rezania; Adam G Goodwill; Brian P McCarthy; Scott A Persohn; Paul R Territo; Jeffrey A Kline
Journal:  Am J Pathol       Date:  2017-02-07       Impact factor: 4.307

Review 10.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.